Physician profile
Steve Yi
NPI 1710155148
$1,655.64
in general payments reported to CMS, 2019-2025
14 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.76 · 2020: $101 · 2021: $349 · 2022: $329 · 2023: $368 · 2024: $321 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $624.79 | 2021-2025 | Ozempic, Rybelsus |
| Merz North America, INC. | $194.53 | 2023 | Xeomin |
| Glaxosmithkline, LLC. | $187.01 | 2020-2024 | Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $135.21 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.65 | 2020-2021 | |
| Abbvie INC. | $79.77 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $64.22 | 2024-2025 | Farxiga, Airsupra |
| Biohaven Pharmaceutical Holding Company Ltd. | $62.33 | 2022 | |
| Abiomed | $56.59 | 2024 | Impella |
| Pfizer INC. | $42.38 | 2023-2024 | |
| Arbor Pharmaceuticals, INC. | $36.29 | 2021 | |
| Genentech USA, INC. | $33.67 | 2021-2022 | |
| Zyla Life Sciences, INC. | $29.29 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $22.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Yi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.